Section Resources

James Aisenberg, M.D.

Dr. Aisenberg is an Associate Clinical Professor of Medicine at The Mount Sinai Hospital, New York. He graduated from Harvard Medical School, trained in internal medicine at The Columbia-Presbyterian Medical Center, and completed his gastroenterology fellowship at The Mount Sinai Hospital. His research focuses on gastrointestinal endoscopy, and also on the impact of common medications on digestive health. He has published over one hundred articles, chapters, and abstracts in leading peer-reviewed journals, and speaks nationally and internationally on gastrointestinal health and disease prevention. He is the President of the Digestive Disease Research Foundation. As featured in The New York Times, from 2003 through the present he has been selected annually by his peers as a “Top Doctor” in New York in the field of gastroenterology.

Academic Appointments:
2005 - present	Associate Clinical Professor,The Mount Sinai School of Medicine, New York, NY
1996 - 2004	Assistant Clinical Professor,The Mount Sinai School of Medicine, New York, NY
1993 - 1996	Instructor in Medicine,The Mount Sinai School of Medicine, New York, NY

Hospital Appointments:
2005 - present	Associate Attending,The Mount Sinai Hospital, New York, NY
1996 - 2004	Assistant Attending,The Mount Sinai Hospital, New York, NY
1993 - 1996	Clinical Assistant,The Mount Sinai Hospital, New York, NY

Education:
1983-1987	Harvard Medical School, Boston, MA, M.D.
1977-1981	Harvard College, Cambridge, MA, BA, magna cum laude

Post Doctoral Training:
1990-1993	Fellow, Div. of Gastroenterology, Mount Sinai Medial Center, N.Y.
1987-1990	Intern and Resident in Internal Medicine, Columbia- Presbyterian Medical Center, New York, NY

Certification:
1993	Diplomat, Gastroenterology, American Board of Internal Medicine (Re-certified 2000, effective through 2010)
1990	Diplomat, Internal Medicine, American Board of Internal Medicine (Re-certified 2000, effective through 2010)

Licensure:
1988	New York State Medical License, (No. 176529)

Honors & Awards:
2009	Fellow, American Gastroenterological Association
2007	Investigator Initiated Research Award from Pfizer Inc (A randomized, single-blind, placebo-controlled, one-week study of the impact of naproxen 500 mg BID, aspirin 81 mg daily, celecoxib 200 mg daily or clopidogrel 75 mg daily on the healing of small gastroduodenal lesions)
2006	Investigator Initiated Research Award from Pfizer Inc (A phase IV, randomized, double blind, placebo-controlled study of the effectiveness of omeprazole 20 mg daily as primary prevention of gastroduodenal injury by naproxen 500 mg BID; J Aisenberg Primary Investigator)
2003	$30,000 grant awarded by Boston Scientific Inc. to Mount Sinai Gastroenterology Division on behalf of Drs. J Aisenberg and LB Cohen for directing Enteryx Physician training program.
2000	Fellow, American College of Physicians
1992	Burrill B. Crohn Foundation Physician Research Award Mount Sinai Medical Center

Other Professional Activities:
2007	Member, Practice Management and Economics Committee,American Gastroenterological Association
2006 - present	Member, Adjudication Committee, GI Reasons Trial, Pfizer Inc.
2003 - present	Digestive Disease Research Foundation. President: 2008-present Co-founder and Medical Director: 2003-2008 DDRF, a 501c3 organization, currently awards two $35,000 grants annually to medical students, permitting them to perform one year of full-time mentored research in gastroenterology. President’s responsibilities include raising funds, directly supervising the Foundation Director in administration of Foundation activities, recruiting board members, running board meetings, participating in grantee selection, and running special events (See: www.digestivedisease.org).
2002 - present	Reviewer for Journal of Clinical Gastroenterology, Alimentary Pharmacology and Therapeutics, Gastrointestinal Endoscopy, Gastroenterology,Digestive Diseases and Sciences
1997 - present	Associate Director, Research Associates of New York. RANY, a physician-owned company, conducts Phase II, III and IV outpatient pharmaceutical and device trials (See: www.centerwatch.com/news-resources/research-centers/profile-details.aspx?ProfileID=541).
1996 - present	Member, American Society for Gastrointestinal Endoscopy
1995 - present	Consultant to numerous pharmaceutical and device manufacturers, including Pfizer, NiCox, Ethicon Endosurgery, Given Imaging.
1994 - 1997	Member, Physician Advisory Group, GI Care Center, Mount Sinai Hospital
1993 - 2001	Member, Executive Committee of Internship Selection Committee, Department of Medicine, Mount Sinai Medical Center
1993 - 1994	Member, GI Care Center re-engineering team, Mount Sinai Hospital
1992 - present	Member, American College of Physicians
1992 - present	Member, American College of Gastroenterology
1991 - present	Member, American Gastroenterology Association
1984 - 1985	Research Associate, Whitaker College of Health Policy Studies, Massachusetts Institute of Technology, Cambridge, MA
1982 - 1983	Research Assistant, Department of Immunopathology, Dana Farber Cancer Institute, Boston, MA
1980 - 1981	Science writer, The Economist, London, England

Teaching Activities:
2007 - present	Mentor, Doris Duke Charitable Foundation
2005 - present	Mentor, Humanities in Medicine program, Mount Sinai Hospital
2003 - present	Mentor, Digestive Disease Research Foundation (Provided one-to-one mentoring to one medical student per year for a full-time in-office research year) These mentorships have resulted in numerous full-length peer-reviewed publications, and national oral and poster presentations (including the 2007 American College of Gastroenterology Presidential Poster Award). The 2007-2008 mentee was awarded graduation with “Distinction in Research” from the Mount Sinai Medical School.
1993 - present	Endoscopy Attending, Mount Sinai Hospital
1993 - present	Medical Ward Attending, Mount Sinai Hospital
1993 - present	Gastroenterology Consult Attending, Mount Sinai Hospital
1993 - present	Invited lecturer at numerous divisional grand rounds and other conferences at Mount Sinai Hospital
1993 - 2002	Director of the Gastroenterology Student Elective, Mount Sinai School of Medicine
1991-1996	Section leader, Medical Student Gastroenterology Pathophysiology Course, Mount Sinai School of Medicine

Office Location(s):

New York Gastroenterology Associates

311 East 79th St.
Suite 2A
New York , New York 10075

Location Phone: (212) 996-6633
Location Fax: (212) 996-6677

Accepting new patients:
I am accepting new patients.

PUBLICATIONS

Original peer-reviewed articles

1. Clayberger C, DeKruyff R, Aisenberg J, Cantor H. Hapten-reactive inducer T-cells. I. definition of two classes of hapten-specific
inducer T-cells. J Exp Med 1983; 157:1906-1919.

2. Sapolsky H, Aisenberg J, Marone J. The call to Rome and other obstacles to state level innovation. Public Admin Rev 1987; 45:137-147.

3. Aisenberg J, Cohen L, Lewis B. Marked endoscopy tubes permit one-pass Ponsky technique. Gastrointestinal Endosc 1991; 37:552.

4. Salomon P, Kornbluth A, Aisenberg J, Janowitz H. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastro 1992; 14:211-5.

5. Aisenberg J, Janowitz H. A cluster of inflammatory bowel disease in three close college friends? J Clin Gastroenterol 1993; 17:18-20.

6. Sperber K, Ogata S, Sylvester C, Aisenberg J, et al. A novel macrophage-derived intestinal mucus secretagogue: Implications for the pathogenesis of inflammatory bowel disease. Gastroenterology. 1993; 104:1302-9.

7. Aisenberg J, Ebert E, Mayer L. T lymphocyte activation by superantigen in the human intestinal mucosa. Gastroenterology 1993; 105:1421-1430.

8. Aisenberg J, Wagreich J, Shim, et al. Anti-neutrophil cytoplasmic antibody and refractory pouchitis: a case-control study. Dig Dis Sci. 1995 Sep; 40(9):1866-1872.

9. Johnson DA, Ganz R, Aisenberg J, et al. Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6 month follow-up of a multi-center trial. Am J Gastroenterology. 2003 Feb; 98(2):250-258.

10. Johnson DA, Ganz R, Aisenberg J, et al. Endoscopic implantation of Enteryx for treatment for GERD: 12 month results of a prospective multicenter trial. Am J Gastroenterol 2003 Sept; 98(2):1921-30.

11. Cohen LB, Dubovsky A, Aisenberg J, et al. Propofol for endoscopic sedation: a protocol for safe and effective administration by the gastroenterologist. Gastrointest Endosc. 2003 Nov; 58(5):725-32.

12. Aisenberg J, Legnani P, Ellozy S, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004 Mar; 99(3):432-41.

13. Cohen LB, Hightower CD, Wood D, Miller KM, Aisenberg J. Moderate level sedation during endoscopy: A prospective study using low-dose propofol, meperidine/fentanyl, and midazolam. Gastrointest Endosc. 2004 Jun; 59(7):795-803.

14. Aisenberg J, Brill JV, Ladabaum U, Cohen LB. Sedation for gastrointestinal endoscopy: New practices, new economics. Am J Gastroenterol 2005 May; 100(5):996-1000.

15. Cohen LB, Johnson DA, Ganz RA, Aisenberg J, et al. Enteryx implantation for GERD: Expanded multicenter trial results and interim postapproval follow-up to 24 months. Gastrointest Endosc. 2005 May; 61(6):650-8.

16. Meier CB, Hegazi RA, Aisenberg J, et al. Innate immune receptor polymorphisms in pouchitis: Is CARD15 a susceptibility factor? Inflamm Bowel Disease. 2005 Nov; 11(11):965-71.

17. Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, Pan S. A multicenter, randomized, double-blind active-comparator, placebo-controlled, parallel-group, comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Clin Ther. 2006 Mar; 28(3):340-51.

18. Cohen LB, Wecsler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, Aisenberg J. Endoscopic sedation in the United States: Results from a nationwide survey. Am J Gastroenterol. 2006 May; 101(5):967-74.

19. Aisenberg J. Cohen LB, Piorkowski JD. Propofol under the direction of trained gastroenterologists: An analysis of the medicolegal implications. Am J Gastroenterol. 2007 Apr; 101:707-713.

20. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007 May 15; 25(10):1211-22.

21. Goldstein JL, Aisenberg J, Zakko SF, Berger MF, Dodge WE. Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or co-administered with celecoxib or naproxen: A randomized, 1-week trial. Digestive Dis Sci. 2008 Mar; 53(3)647-56.

22. Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, Piorkowski JD Jr. AGA Institute review of endoscopic sedation. Gastroenterology. 2007 August; 133(2):675-701.

23. Benson A, Cohen LB, Waye JD, Akhavan A, Aisenberg J. Endoscopic sedation in developing and developed countries. Gut and Liver, 2008; 2:105-112.

24. Desai JC, Sanyal SM, Goo T, Benson AA, Bodian CA, Miller KM, Cohen LB, Aisenberg J. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: A randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2008 Aug; 53(8):2059-65.

25. Marion JF, Waye JD, Present DH, Israel Y, Bodia C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: A prospective endoscopic trial. Am J Gastroenterol. 2008 Sep; 103(9):2342-9.

26. Dikman A, Sanyal S, Von Althann C, Whitson M, Desai J, Bodian C, Brooks A, Bamji N, Cohen L, Miller K, Aisenberg J. A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib, or clopidogrel on gastroduodenal mucosal healing. Aliment Pharmacol Ther. 2009 April 1; 29(7):781-91.

27. Desai J, Goo T, Fukata M, Sanyal S, Dikman A, Miller K, Cohen L, Brooks A, Wang Q, Abreu M, Aisenberg J. NSAID-induced Antral Ulcers are Associated with Distinct Changes in Mucosal Gene Expression. Aliment Pharmacol Ther. 2009 July 1; 30(1): 71-81.

Case Reports:

Cunningham JD, Vine AJ, Karch L, Aisenberg J. The role of laparoscopy in the management of intussusception in the Peutz-Jeghers Syndrome: Case report and review of the literature. Surg Laparosc Endosc. 1998 Feb; 8(1):17-20.

Books & Chapters in Books:

1. Greenstein A, Aisenberg J. Clinical picture of Crohn's Disease: upper gastrointestinal tract. In Korelitz B, Pratera C (editors). Crohn's Disease, New York 1996; Marcel Dekker, Inc., pp 259-276.

2. Aisenberg J, Cohen LB. Sedation in endoscopic practice. Gastrointest Endosc Clin N Am. 2006 Oct; 16(4):695-708.

3. Cohen LB, Aisenberg J. Sedation for colonoscopy. In Waye J, Rex D, Williams CB (editors). Colonoscopy Principles and Practice, New York 2009; Wiley-Blackwell.

4. Cohen LB and Aisenberg J. (Editors). Endoscopic Sedation: Preparing for the Future. Gastrointest Endosc Clin N Am. 2008. Philadelphia: Elsevier Saunders.

5. Aisenberg, J. Endoscopic sedation: Equipment and personnel. Gastrointest Endosc Clin N Am. 2008 Oct; 18(4):641-9.

Invited Contributions:

1. Aisenberg J. Commercialization of research: So far. Nature 1982; 297:617.

2. Aisenberg J, Castell D. Approach to the patient with unexplained chest pain. Mt Sinai J
of Medicine 1994 Nov; 61(6):476-483.

3. Aisenberg J, Waye JD. Capsule enteroscopy in India: Early steps. Indian J Gastroenterol.
2006 Jul-Aug; 25(4):177-8.

4. Aisenberg J, Cohen L. Sedation in endoscopic practice. Gastrointest Endosc.
Clin North Am. 2006 Oct; 16(4):695-708.

5. Aisenberg J. Endoscopic sedation: Equipment and personnel. Gastrointest Endosc.
Clin North Am. 2008 Oct; 18(4):641-49

6. Aisenberg, J. Gastrointestinal endoscopy nears “the molecular era.” Gastrointest Endosc.
2008 Sept; 68(3):528-30.

7. Aisenberg J. Bowel preparation for colonoscopy: Shortening the “runway time.” Gastrointest
Endosc. 2009 Mar; 69(3):707-9.

Abstracts:

1. Aisenberg J, Posnett D, Pizzimenti A, Mayer L. Do normal and/or diseased intestinal
epithelial cells express superantigens? Gastroenterology 1992; 102:A588.

2. Aisenberg J, Mayer L. Presentation of superantigens to T lymphocytes by normal
human epithelial cells. Oral presentation at Digestive Disease Week, 1993. Gastroenterology 1993; 104:A659.

3. Aisenberg J, Sperber K, Sylvester C, et al. Macrophage-derived mucus secretagogue,
a product of lamina propia macrophages, induces mucus release from normal and inflammatory bowel disease epithelium. Gastroenterology 1992; 102:A599.

4. Aisenberg J, Zelman G, Bodian C, Sachar D. Serologic analysis permits differentiation
of Crohn’s disease from ulcerative colitis. Gastroenterology 1998; 114; A918.

5. Johnson DA, Aisenberg J, Cohen LB, et al. Enteryx solution, a minimally invasive injectable treatment for GERD: Initial multicenter human trial results. Am J Gastroenterol 2001; 96:S17.

6. Lehman G, Aisenberg J, Cohen L, et al. Enteryx Solution, a minimally invasive injectable
treatment for GERD: International trial results. Gastroenterology 2002; 122:A101.

7. Lehman G, Aisenberg J, Cohen L, et al. Improvement in esophageal pH probe studies after Enteryx therapy for GERD. Gastroenterology 2002; 122:A89.

8. Johnson DA, Aisenberg J, Cohen L, et al. Enteryx, an injectable treatment for
GERD: Multicenter results. Am J Gastroenterol 2002; 97:S12.

9. Goldstein J, Eisen G, Lewis B, Gralnick I, Fort J, Brown R, Johanson J, Aisenberg J, Arbir N, Zlotnick S. Abnormal small bowel findings are common in healthy subjects screened for a multi-center, double blind, randomized placebo-controlled trial utilizing capsule endoscopy. Gastroenterology 2003; 124:A37.

10. Lehman, G, Hieston K, Aisenberg J, et al. Enteryx solution, a minimally invasive injectable treatment for GERD: Current worldwide multi-center human trial results. Gastroenterology 2003; 124:P68.

11. Johnson D, Aisenberg J, Cohen L et al. Enteryx Solution, a minimally invasive injectable treatment for GERD: Analysis of x-ray findings over 12 months. Gastroenterology 2003; 124:P163.

12. Lehman GA, Hieston KJ, Aisenberg J, Cohen LB, Miller KM, Dsouza C, et. al. Enteryx solution, a minimally invasive injectable treatment for GERD: Current worldwide multi-center human trial results. Gastrointest Endosc 2003; 57:672.

13. Cohen LB, Johnson JA, Aisenberg J, Foley TR, Ganz R, Lehman G. Enteryx solution, a minimally invasive injectable treatment for GERD: analysis of extended follow-up through 24-months. Am J Gastroenterol 2003; 98:71.

14. Lehman G, Hieston KJ, Johnson D, Stacy T, Mosconi B, Friberg S, Aisenberg J, et al. Enteryx solution, a minimally invasive injectable treatment for GERD: analysis of ph-metry and manometry findings over 12 months. Gastroenterology 2003; 124:P164.

15. Aisenberg J, Cohen L, Foley TR, et al. Enteryx solution, a minimally invasive injectable treatment for GERD: The private practice experience. Gastroenterology 2003; 124:P164.

16. Ganz R, Aisenberg J, Cohen L, et al. Enteryx solution, a minimally invasive injectable treatment for GERD: Analysis of endoscopy findings at 12 months. Gastroenterol 2003; 124:P164.

17. Cohen LB, Hightower CD, Wood DA, Miller KM, Aisenberg J. Moderate-level sedation during endoscopy using low-dose propofol, midazolam and an opioid. Gastrointest Endosc 2004; 59:AB127.

18. Lehman GA, Hieston K, Cohen LB, D’Souza C, Aisenberg J, Ganz R, et. al. Correlation between clinical outcome and Enteryx implant shape. Gastrointest Endosc 2004; 59:AB149.

19. Deviere J, Cohen LB, Aisenberg J, Ganz R, Lehman GA, Foley TR, et. al. Predictors of Enteryx outcomes at 12 months. Gastrointest Endosc 2004; 59:AB243.

20. Johnson DA, Aisenberg J, Cohen LB, Ganz R, Lehman GA, Foley TR, et. al. Clinical benefits of Enteryx for high-dose PPI-patients. Gastrointest Endosc 2004; 59:AB245.

21. Cohen LB, Hightower CD, Wood DA, Wecsler J, Gaetano JN, Miller KM, Aisenberg J. Wireless pH-metry combined with surveillance endoscopy in Barrett’s esophagus. Am J Gastroenterol 2004; 99:35.

22. Cohen LB, Dubovsky A, Gaetano JN, Wecsler J, Miller KM, Aisenberg J. Endoscopic sedation: A survey of patient attitudes and expectations during colonoscopy. Am J Gastroenterol 2004; 99:908.

23. Cohen LB, Aisenberg J, Foley TR, Ganz RA, Johnson DA, Lehman G, et al. Enteryx®: Worldwide pivotal studies in 237 patients. Am J Gastroenterol 2004; 99:897.

24. Johnson DA, Aisenberg J, Cohen LB, Foley TR, Ganz RA, Lehman G. Durability and long-term safety of Enteryx implantation for GERD: 24-month follow-up of a prospective multicenter trial. Am J Gastroenterol 2004; 99:904.

25. Cohen LB, Wecsler JS, Gaetano JN, Durkalski V, Miller KM, Aisenberg J. Endoscopic sedation in the United States in 2004: Results from a postal survey of 5000 gastroenterologists. DDW, 2005.

26. Cohen LB, Weitman ES, Voynarovska M, Miller KM, Aisenberg J. Gastroenterologist-directed propofol, midazolam and fentanyl for endoscopic sedation: Adverse events during 4,213 procedures. DDW, 2005.

27. Lehman GA, Aisenberg J, Cohen LB, Foley TR, Ganz RA, Johnson DA. Endoscopic implantation of Enteryx® for the treatment of GERD: 36-month follow-up in 46 Subjects. Gastroenterol 2005; A46.

28. Meier C, Aisenberg J, Legnani P, et al. Innate immune receptor polymorphisms in pouchitis: Is NOD2/CARD15 a susceptibility factor? Gastroenterol. 2005; 128:A112.

29. Goldstein JL, Eisen G, Kivitz A, Aisenberg J, et al. Valdecoxib is associated with a lower incidence of endoscopic gastroduodenal ulcers the naproxen in healthy subjects aged 65-75. Gastroenterol. 2005; 128:A24.

30. Cohen LB, Akhavan A, Benson A, Bodian C, Miller KM, Aisenberg J. Propofol versus Propofol-Meperidine-Midazolam for Upper Endoscopy: A Cross-over Study Comparing Parameters of Sedation and Recovery. DDW, 2006.

31. Cohen LB, Waye JD, Benson A, Akhavan A, Bodian C, Miller KM, Aisenberg J.
Sedation Practices Worldwide: Results from an International Survey of Expert Endoscopists. DDW, 2006.

32. Goldstein JL, Aisenberg J, Berger M, Dodge WE. Effects of concomitant aspirin (81 mg) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: A randomized, placebo controlled trial. Gastroenterol 2006; 130:P105.

33. Cohen LB, Holub J, Lieberman DA, Desai J, Aisenberg J. Does routine use of supplemental oxygen during endoscopy really reduce the risk of cardiopulmonary complications? Gastroenterol 2007; 132:P72.

34. Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M Abreu MT, Ullman TA, Aisenberg J, Mayer LF. Methylene blue dye-spray targeted biopsies are superior to standard colonoscopic surveillance biopsies in detecting dysplasia in patients with ulcerative and Crohn’s colitis: A prospective endoscopic trial. Gastroenterol 2007; 132:P61.

35. Desai JC, Sanyal SM, Goo T, Benson AA, Bodian CA, Miller KM, Cohen LB, Aisenberg J. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: A randomized, double-blind, placebo-controlled study. Presidential Poster Award. American College of Gastroenterology, Philadelphia, 2007.

36. Marion JF, Waye JD, Present DH, Yuriy I, Bodian CA, Harpaz N, Chapman ML, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Itzkowitz SH, Mayer L. Follow-up chromoendoscopy continues to be superior to standard colonoscopic surveillance for managing dysplasia in patients with IBD: A long-term, prospective, endoscopic trial. Gastroenterol. 2008; 134:A34.

37. Dikman A, Sanyal S, Aisenberg J, Miller KM, Cohen LB. Gastroenterologist-Directed, Balanced Propofol Sedation for EGD and Colonoscopy: an Analysis of Safety in 15,286 Patients. Gastrointest Endosc 2008;67:AB84.

38. Desai JC, Goo T, Fukata M, Sanyal S, Dikman AE, Miller KM, Cohen LB, Brooks A, Abreu MT, Aisenberg J. NSAID-induced antral ulcers correlate with distinct changes in antral gene expression. Gastroenterol. 2008; 134.

39. Ryskina, KL, Miller KM, Aisenberg J, Herron DM, Kini SU. Routine management of stricture after gastric bypass and predictors of subsequent weight loss. Gastroenterol. 2008; 134:A371.

40. Mendoza JL, Marotta M, Denchy RA, Kornbluth A, Ullman TA, Mayer L, Erazo M, Felman S, Im J, Rubin P, Lichtiger S, Weiss AA, Aisenberg J, Miller KM, Goldstein ES, Bauer JJ, Jaffin BW, Present DH, Abreu MT, Mitchell AA. Innate immune defects in IRGM1, TLR2, and NOD2 contribute to Crohn’s disease risk and severity in Ashkenazi Jews. Gastroenterol. 2008; 134.

41. Dikman A, Sanyal S, von Althann C, Whitson M,. Desai J, Bamji N, Cohen L, Miller K, Aisenberg J. Is Endoscopic Biopsy Safe in Patients Receiving Anti-Platelet Agents? DDW, 2009 (plenary presentation).

Invited Lecture / Presentations (since 2003):

1. Aisenberg J. How will the M2A capsule change gastroenterology practice? Gastroenterology Grand Rounds, Lenox Hill Hospital, January 2003.

2. Aisenberg J. Capsule endoscopy in clinical practice. Course Faculty Member for two-day training course for practicing physicians. New York. April 2003.

3. Aisenberg J. Enteryx – physician training course. Course Director. Indianapolis University. April 2003.

4. Aisenberg J. Capsule endoscopy in clinical practice. Course Faculty Member for two-day training course for practicing physicians. Boston. August 2003.

5. Aisenberg J. How will the M2A capsule change gastroenterology practice? Gastroenterology Grand Rounds, North Shore University Hospital, November 2003.

6. Aisenberg J. Enteryx treatment for GERD. Sponsored Symposium on Endoscopic Treatment for GERD for New York Society of Gastrointestinal Endoscopy annual course, December 2003.

7. Aisenberg J. Enteryx – physician training course. Course Director. Mount Sinai (NY). December 2003.

8. Aisenberg J. Enteryx – physician training course. Course Director. Mount Sinai (NY). June 2004.

9. Aisenberg J. Should we care who sedates our patients? Symposium on Endoscopic Sedation. New York, NY. November 2004.

10. Aisenberg J. Coxibs and the GI tract: 2005. Pfizer Investigator Meeting, San Juan, PR. February 2005.

11. Aisenberg J. Does aspirin eliminate the coxib GI advantage? Pfizer Investigator Meeting, Charleston, NC. February 2005.

12. Aisenberg J. GI-directed propofol use: An assessment of safety and efficacy. Symposium on Endoscopic Sedation. New York, NY. November 2005.

13. Aisenberg J. The future of endoscopic sedation: The gastroenterologist’s perspective. Symposium on Endoscopic Sedation. New York, NY. November 2005.

14. Aisenberg J. Enteryx. Annual Meeting of New York Society for Gastrointestinal Endoscopy, December 2005.

15. Aisenberg J. NSAIDs in inflammatory bowel disease. Gastroenterology Inflammatory Bowel Disease Conference, Mount Sinai Hospital. May 2006.

16. Aisenberg J. GI-directed propofol: How can we manage risk? Symposium on Endoscopic Sedation. New York, NY. November 2006.

17. Aisenberg J. Current issues and controversies in endoscopic sedation. Regional meeting of American College of Gastroenterology. New York. March, 2007.

18. Aisenberg J. Extended monitoring for endoscopy: is it worth it? ASGE Clinical Symposium. Digestive Disease Week. Washington D.C. May 2007.

19. Aisenberg J. Personnel and equipment? Symposium on Endoscopic Sedation. New York, NY. November 2007.

20. Aisenberg J, Reich D, Feld A. Managing risk: an analysis of propofol use by non-anesthesiologists. Symposium on Endoscopic Sedation. New York, NY. November 2007.

21. Aisenberg J. Current issues and controversies in endoscopic sedation. Regional Meeting of American College of Gastroenterology. New York. March 2008.

22. Aisenberg J. Advances in technology for sedation. New York Society for Gastrointestinal Endoscopy. New York. October 2008.

23. Aisenberg, J. Conventional methods for sedation. American College of Gastroenterology Regional Postgraduate Course. New York. March 2009.

Updated 04/09